Genmab A/S is an international biotechnology company founded in 1999, headquartered in Copenhagen, Denmark. The company specializes in developing innovative antibody therapeutics aimed at transforming the treatment of cancer and other serious diseases. Their work centers on pioneering antibody science to create next-generation therapeutics that address significant unmet medical needs in oncology and beyond.

Genmab has developed several marketed antibody products including Daratumumab (Darzalex) for multiple myeloma and AL amyloidosis, Ofatumumab (Kesimpta) for relapsing multiple sclerosis, and Teprotumumab (Tepezza) for thyroid eye disease. These products are often developed and commercialized through partnerships with major pharmaceutical companies such as Janssen, Novartis, and Amgen. The company’s proprietary technologies include HexaBody, DuoBody, DuoHexaBody, and HexElect, which enable the development of differentiated human antibody therapies.

Beyond its core antibody development, Genmab emphasizes collaborations that leverage its expertise to co-develop and commercialize therapeutics globally. With operations extending into Denmark, the Netherlands, Japan, and the US, Genmab combines scientific innovation with global reach in its commitment to improving patient outcomes.

The company marks its 25th anniversary highlighting its journey from a start-up to a leading biotech innovator, driven by data and rooted in science. Genmab’s mission and tagline, “Engineering a transformative tomorrow,” encapsulate its vision to harness the power of scientific discovery and technology to pioneer new treatment options in cancer and serious diseases.

Genmab’s commitment to innovation and partnership continues to position it as a key player in the biotechnology industry focused on therapeutic antibodies, with a strong portfolio of approved medicines and a robust pipeline advancing new cancer therapies and treatments for other serious conditions.